The treatment of malignant mesothelioma (MPM) remains inadequate. New therapies, such as gene therapy? or immuno-gene therapy, are desperately needed. This Project is based on a previous series of Phase I? clinical trials using recombinant, replication-deficient adenoviral (Ad) vectors containing the Herpes Simplex? Thymidine Kinase (HSVtk) gene in 34 MPM patients. Significant intratumoral HSVtk gene transfer was? achieved and some radiographic and clinical responses were noted, including 2 patients who had durable? complete responses in delayed fashion, highly suggestive of anti-tumor immune responses. On this basis,? the focus of laboratory and clinical work was shifted to genetic immunotherapy of thoracic malignancies.? Based on strong preclinical data, a new Phase I clinical trial using a single dose of intrapleural adenoviral? interferon beta (Ad.lFN-beta) for patients with MPM and malignant pleural effusions (MPE) was conducted.? The approach was safe and a number of immunologic responses, as well as clinical responses were? observed. The goal of this Project is to continue and extend these clinical trials aimed at patients with? mesothelioma. In the first aim, a Phase 1 trial will be conducted to assess the safety, toxicity profile, immune? responses, and clinical effect of two intrapleural doses of Ad.lFN-beta for patients with MPE/MPM. Specific? Aims 2 and 3 will consist of Phase 2 clinical trials testing approaches in patients with MPM that were? developed from our preclinical studies to augment efficacy.
Aim 2 will determine the efficacy and immune? responses associated with the delivery of two doses of Ad.lFN-beta as neo-adjuvant therapy in combination? with surgical debulking and adjuvant COX-2 inhibitors in patients with MPM.
Aim 3 will determine the? efficacy and immune responses associated with the delivery of two doses of Ad.lFN-beta in combination with? chemotherapy and adjuvant COX-2 inhibitors in patients with MPM.
In Aim 4, investigators will begin the? steps needed to develop an adoptive immunotherapy trial using genetically engineering T-lymphocytes? reactive against mesothelin for patients with mesothelioma and other tumors expressing this tumor antigen? after preclinical optimization.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA066726-12
Application #
7664441
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2008-08-01
Budget End
2009-07-31
Support Year
12
Fiscal Year
2008
Total Cost
$485,852
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Aggarwal, Charu; Haas, Andrew R; Metzger, Susan et al. (2018) Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion. Mol Ther 26:1198-1205
Moon, Edmund K; Wang, Liang-Chuan S; Bekdache, Kheng et al. (2018) Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines. Oncoimmunology 7:e1395997
Klampatsa, Astero; Haas, Andrew R; Moon, Edmund K et al. (2017) Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM). Cancers (Basel) 9:
Moon, Edmund K; Ranganathan, Raghuveer; Eruslanov, Evgeniy et al. (2016) Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer. Clin Cancer Res 22:436-47
Liu, X; Barrett, D M; Jiang, S et al. (2016) Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice. Blood Cancer J 6:e430
Liu, Xiaojun; Ranganathan, Raghuveer; Jiang, Shuguang et al. (2016) A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors. Cancer Res 76:1578-90
O'Hara, Mark; Stashwick, Caitlin; Haas, Andrew R et al. (2016) Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy. Immunotherapy 8:449-60
Sterman, Daniel H; Alley, Evan; Stevenson, James P et al. (2016) Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFN? Combined with Chemotherapy. Clin Cancer Res 22:3791-800
Newick, Kheng; O'Brien, Shaun; Sun, Jing et al. (2016) Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization. Cancer Immunol Res 4:541-51
Andy, Uduak U; Harvie, Heidi S; Smith, Ariana L et al. (2015) Validation of a self-administered instrument to measure adherence to anticholinergic drugs in women with overactive bladder. Neurourol Urodyn 34:424-8

Showing the most recent 10 out of 85 publications